174 related articles for article (PubMed ID: 1850660)
1. Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM; Kerns BJ; Iglehart JD; Marks JR
Cancer Res; 1991 May; 51(10):2605-10. PubMed ID: 1850660
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
3. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bartek J; Iggo R; Gannon J; Lane DP
Oncogene; 1990 Jun; 5(6):893-9. PubMed ID: 1694291
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
5. Relation between p53 overexpression and established prognostic factors in breast cancer.
Davidoff AM; Herndon JE; Glover NS; Kerns BJ; Pence JC; Iglehart JD; Marks JR
Surgery; 1991 Aug; 110(2):259-64. PubMed ID: 1858036
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
7. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
[TBL] [Abstract][Full Text] [Related]
9. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations and expression in breast carcinoma in situ.
Lukas J; Niu N; Press MF
Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
[TBL] [Abstract][Full Text] [Related]
11. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
[TBL] [Abstract][Full Text] [Related]
12. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
13. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components.
Lien HC; Lin CW; Mao TL; Kuo SH; Hsiao CH; Huang CS
J Pathol; 2004 Oct; 204(2):131-9. PubMed ID: 15376261
[TBL] [Abstract][Full Text] [Related]
14. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression.
Ruggeri B; Caamano J; Goodrow T; DiRado M; Bianchi A; Trono D; Conti CJ; Klein-Szanto AJ
Cancer Res; 1991 Dec; 51(24):6615-21. PubMed ID: 1742735
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of hTERT mRNA in breast carcinoma and its relation to p53].
Tang F; Gu DH; Wang H; Zhu TF; Zhu HG; Xu ZD; Hu XQ
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):192-5. PubMed ID: 16875603
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of p53 protein is common in premalignant head and neck lesions.
Pavelic ZP; Li YQ; Stambrook PJ; McDonald JS; Munck-Wikland E; Pavelic K; Dacic S; Danilovic Z; Pavelic L; Mugge RE
Anticancer Res; 1994; 14(5B):2259-66. PubMed ID: 7840533
[TBL] [Abstract][Full Text] [Related]
19. Increase of GKLF messenger RNA and protein expression during progression of breast cancer.
Foster KW; Frost AR; McKie-Bell P; Lin CY; Engler JA; Grizzle WE; Ruppert JM
Cancer Res; 2000 Nov; 60(22):6488-95. PubMed ID: 11103818
[TBL] [Abstract][Full Text] [Related]
20. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression.
Fontanini G; Vignati S; Bigini D; Merlo GR; Ribecchini A; Angeletti CA; Basolo F; Pingitore R; Bevilacqua G
J Pathol; 1994 Sep; 174(1):23-31. PubMed ID: 7965400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
